Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced it has appointed Henry ...

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension ...

Researchers from The University of Osaka find that chronic liver congestion is linked to severe liver diseases through a specific signaling pathway in ...

Lots of Americans have a blood pressure problem, but plenty aren’t doing much to remedy it, according to research published today. Scientists studied nationally representative data from Americans over ...

National data showed 79% of adults with hypertension didn't have their blood pressure within the blood pressure goal recommended by guidelines. Most of those uncontrolled hypertension cases went ...

Chinese Medical Journals Publishing House Co., Ltd. Portal hypertension, a life-threatening complication of cirrhosis affecting millions globally, has seen paradigm shifts with the release of the ...

Please provide your email address to receive an email when new articles are posted on . Lifetime risk for hypertension is up to 90% among U.S. adults. Updated guidelines and a pipeline of novel drugs ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Lactulose and tai chi can prevent falls in patients with cirrhosis, according to results from the LiveSMART Trial. Michigan Medicine hepatologists reported the findings as a late breaking abstract at ...